Evidence map›Paper›PMID 31118445›Full record

Observational studyScientific reports2019

The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study.

Xiaoling Cai, Dayi Hu, Changyu Pan, Guangwei Li, Juming Lu, Qiuhe Ji, Benli Su, Haoming Tian, Shen Qu, Jianping Weng and 3 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01525693 (Evaluation of Effectiveness of Treatment Paradigm for Newly Diagnosed Type 2 Diabetes Patients in China), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01525693 unknown statusnot on this map

Evaluation of Effectiveness of Treatment Paradigm for Newly Diagnosed Type 2 Diabetes Patients in China (NEW2D STUDY) A Study Of China Cardiometabolic Registries (CCMR)

TypeobservationalSponsorChina Cardiometabolic RegistriesRan2012 to 2014Enrolled5,000ConditionsType 2 Diabetes
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Xiaoling CaiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Dayi HuDepartment of Cardiology, Peking University People's Hospital, Beijing, China.
Changyu PanDepartment of Endocrinology and Metabolism, Chinese People's Liberation Army General Hospital, Beijing, China.
Guangwei LiDepartment of Endocrinology and Metabolism, Fuwai Hospital, Beijing, China.
Juming LuDepartment of Endocrinology and Metabolism, Chinese People's Liberation Army General Hospital, Beijing, China.
Qiuhe JiDepartment of Endocrinology and Metabolism, The Forth Military Medical University Xi Jing Hospital, Xian, China.
Benli SuDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital Dalian Medical University, Dalian, China.
Haoming TianDepartment of Endocrinology and Metabolism, Sichuan University West China Hospital, Chengdu, China.
Shen QuDepartment of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Shanghai, China.ORCID http://orcid.org/0000-0003-0811-7070
Jianping WengDepartment of Endocrinology and Metabolism, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Danyi ZhangVitalStrategic Research Institute, Shanghai, China.
Jie XuVitalStrategic Research Institute, Shanghai, China.
Linong JiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. jiln@bjmu.edu.cn.
Peking University · CNPeople's Liberation Army No. 150 Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNDalian Medical University · CNShanghai Tenth People's Hospital · CNSichuan University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nationwide data on glycemic control, blood pressure (BP) control and lipid control in patients with newly diagnosed type 2 diabetes were vacant in China. The aim of this study was to assess the clinical outcomes for these patients. This is an observational prospective cohort study with 12 months of follow up. Patients with a diagnosis of type 2 diabetes less than 6 months were enrolled. Hemoglobin A1c (HbA1c) levels, BP levels and lipid levels were collected at baseline and the follow-ups. This study was registered at www.clinicaltrials.gov (NCT01525693). A total of 5770 participants from 79 hospitals across six geographic regions of China were recruited. After 12 months of treatment, 68.5% of these patients achieved HbA1c <7.0%; 83.7% reached BP <140/90 mmHg; 48.2% met low density lipoprotein cholesterol (LDL-c) <2.6 mmol/L; and 29.5% of patients reached the combined three therapeutic targets. Compared to those patients with baseline HbA1c <7.0%, patients with baseline HbA1c ≥7.0% had higher failure rate to reach glycemic control (relative risk (RR) = 2.04, p < 0.001), BP control (RR = 1.21, p < 0.001) and LDL-c control (RR = 1.11, p < 0.001). Obese patients had higher possibilities of failure in glucose control (RR = 1.05, p = 0.004), BP control (RR = 1.62, p < 0.001) and lipid control (RR = 1.09, p = 0.001) than patients with normal weight. The active smokers were more likely to fail in glycemic control than non-smokers (RR = 1.06, p = 0.002), and patients with physical activities were less likely to fail in lipid control than patients without exercises (RR = 0.93, p = 0.008). This study outlined the burdens of glycemic control, blood pressure control, lipid control in newly diagnosed type 2 diabetic patients in China, identified gaps in the quality of care and risk-factor control and revealed the factors influencing these gaps.

Indexed as

AdultAgedAged, 80 and overBlood GlucoseChinaCholesterol, LDLCombined Modality TherapyDiabetes Mellitus, Type 2DyslipidemiasFemaleGlycated HemoglobinHumansHypertensionHypoglycemiaHypoglycemic AgentsInsulinBlood GlucoseCholesterol, LDLGlycated HemoglobinHypoglycemic AgentsInsulin

Identifiers

PMID31118445
PMCPMC6531462
OpenAlexW2945524795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.